Z Mao, H Xiao, P Shen, Y Yang, J Xue, Y Yang… - Cell discovery, 2022 - nature.com
KRAS mutation occurs in nearly 30% of human cancers, yet the most prevalent and
oncogenic KRAS (G12D) variant still lacks inhibitors. Herein, we designed a series of potent …